



The Canadian Vaccine Catalogue

Working Group Meeting - COVID Terminology

December 9, 2020

Attendees

- Andrea MacLean, Canada Health Infoway
- Arielle Goldman Smith, Shared Health Manitoba
- Cameron Bell, CANImmunize
- Dennis Sharkey, BCCDC
- Fariba Behzadi, Ministry of Health Ontario
- Helen Xing, BCCDC
- Igor Sirkovich, Ministry of Health Ontario
- Jayne Boutilier, Nova Scotia
- Joy Pulickal, PHAC
- Kelly Davison, Canada Health Infoway
- Linda Parisien, Canada Health Infoway
- Lori Kane, Ministry of Health Ontario
- Marc L'Arrivee, Shared Health Manitoba
- May Canning, BCCDC
- Roger Cheng, CIHI
- Ruth Deane, Shared Health Manitoba
- Taylor Rubens-Augustson, CANImmunize
- Tracy Alderson, Shared Health Manitoba

Agenda

Objective: to review proposed COVID-19 concepts and reach consensus on what will be included in the December 11 CVC release.

- Review of proposed COVID-19 trade name concepts
- Review of proposed COVID-19 generic concepts
- COVID-19 Abbreviations
- Additional changes in CVC release 1.1.6
- Implementation
- Questions/Discussion

Proposed Trade Name Concept - Pfizer

ConceptID	28581000087106
Fully Specified Name	PFIZER-BIONTECH COVID-19 messenger Ribonucleic Acid 30 micrograms per 0.3 milliliter powder and diluent for solution for injection BioNTech Manufacturing GmbH (medicinal product)
Preferred Term	COVID-19 PFIZER-BIONTECH COVID-19 mRNA BTM
Synonym	PFIZER-BIONTECH COVID-19 messenger Ribonucleic Acid 30 micrograms per 0.3 milliliter powder and diluent for solution for injection BioNTech Manufacturing GmbH

Proposed Trade Name Concept - Moderna

ConceptID	28571000087109
Fully Specified Name	MODERNA COVID-19 messenger Ribonucleic Acid-1273 100 micrograms per 0.5 milliliter liquid for injection Moderna Therapeutics Inc. (medicinal product)
Preferred Term	COVID-19 MODERNA COVID-19 mRNA-1273 MT
Synonym	MODERNA COVID-19 messenger Ribonucleic Acid-1273 100 micrograms per 0.5 milliliter liquid for injection Moderna Therapeutics Inc.

Proposed Generic Concept - High level

ConceptID	28531000087107
Fully Specified Name	Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)
Preferred Term	COVID-19 unspecified COVID-19 non spécifié
Synonyms	<ul style="list-style-type: none">• Novel coronavirus vaccine• Vaccine against COVID-19• Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2• Vaccine product for prevention of disease caused by Severe acute respiratory syndrome coronavirus 2

Proposed Generic Concept - mRNA specific

ConceptID	1119349007
Fully Specified Name	Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product)
Preferred Term	? <i>Currently in CVC: Severe acute respiratory syndrome coronavirus 2 mRNA only vaccine product</i>
Synonyms	?

Question: do we need to include this concept in the CVC?

ConceptID	1119305005
Fully Specified Name	Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 antigen (medicinal product)
Preferred Term	?
Synonyms	?


COVID-19 Disease Concept

ConceptID	840539006
Concept name	Disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder)
Display name in CVC (en)	COVID-19
Display name in CVC (fr)	COVID-19

COVID-19 Antigen Concept

ConceptID	840536004
Concept name	Antigen of Severe acute respiratory syndrome coronavirus 2 (substance)
Display name in CVC (en)	Antigen of SARS-CoV-2
Display name in CVC (fr)	antigène du SARS-CoV-2

Agent-Antigen-Disease COVID-19 Mappings



COVID-19 vaccineRouteOfAdminMap

1. Addition of COVID-19 PFIZER-BIONTECH COVID-19 mRNA BTM (ConceptID: 28581000087106) → Intramuscular: IM (ConceptID: 78421000)
2. Addition of COVID-19 MODERNA COVID-19 mRNA-1273 MT (ConceptID: 28571000087109) → Intramuscular: IM (ConceptID: 78421000)

Abbreviations

- Generic agent abbreviation: COVID-19
- Discussion - necessary to uniquely identify trade name product in abbreviation?

Additional Changes in CVC release 1.1.6

Trade Name Subset

1. Addition of Flucelvax Quad®

28491000087107 |FLUCELVAX QUAD 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (medicinal product)|

2. Two row updates, 2 field updates

→ DIN for HB Engerix B GSK

→ DIN for HB Engerix B pediatric GSK

Agent-antigen-disease Mapping



Additional Changes in CVC release 1.1.6

Lot Data

1. Month of November added (15 additions, 63 row updates, 63 field updates, 1 deletion)

GTINs

1. Two row updates, two field updates
 - ConceptID for Engerix - B, Hepatitis B Vaccine
 - ConceptID for Engerix - B (Junior), Hepatitis B Vaccine

vaccineRouteOfAdminMap

1. Addition of Flucelvax ® Quad (ConceptID: 28491000087107) → Intramuscular: IM (ConceptID: 78421000)

Implementation

- In scope for December 11, 2020 CVC release
- To be notified, sign up for CVC updates: <https://bit.ly/3fKt8HZ>

Questions/Discussion/Updates

- RFC submitted to create a concept for Influsplit Tetra
 - Further evidence was required to support the RFC indicating that Influsplit Tetra is the same product as Fluarix Quadrivalent, as shown on the U.S. product monograph that was provided. Has been submitted and awaiting a response.
- Research in progress to understand if GamaSTAN and GamaSTAN S/D are distinct products, which will inform the RFC process
 - Reached out to manufacturer, awaiting response
- RFC to be submitted for Canadian PT for COVID-19 mRNA generic concept